EUROPA lasEr-driven Universal Radio-isOtope Production Accelerator
- Coordinator
- Institut Mines-Telecom, France
- Runs
- 1 April 2026 to 31 March 2030
- Status
- Running
- EU funding
- €3.5m
- Total cost
- €3.7m
- Partners
- 15 organisations in 6 countries
- Type
- European Innovation Council
- Grant agreement
- 101257418
What the project is doing
In the project's own words, from its summary on CORDIS.
EUROPA envisions an innovative Artificial Radioisotope (ARI) production facility based on laser-plasma acceleration (LPA), leveraging its versatility to produce innovative radiopharmaceuticals for diagnosing and treating a wide range of cancers. For the first time, EUROPA will demonstrate that LPA can produce ARIs with sufficient activity (in Bq) and quality for medical research. This enables compact, easy-to-deploy ARI production units suitable for deployment in hospitals, offering a wide range of ARIs.
Nuclear medicine is increasingly favored for cancer diagnosis and treatment, due to far fewer side effects than chemotherapy. However, it requires extensive preclinical investigations to study a broad array of ARIs to treat various types of cancer. Currently, ARIs are produced by a limited number of nuclear reactors and accelerators that cannot meet the rising demand for novel isotopes in nuclear medicine. LPA offers a highly versatile source of radiation (gamma rays) and particles (ions and neutrons) across a broad energy spectrum, making it a promising approach for generating the moderate activity levels required for innovative radiopharmaceutical applications.
To demonstrate this potential, EUROPA focuses on two innovative pairs of theranostic ARI: 61Cu/67Cu and 43Sc/47Sc. The project aims to optimize LPA mechanisms to enhance the yield of accelerated particles within the desired energy range, while developing dedicated detectors to support proof-of-concept experiments for radioisotope production. Furthermore, EUROPA investigates ways to increase the laser repetition rate, thereby improving the average particle current—an essential step toward transitioning from scientific proof to technological application.
Bringing together top experts in radiopharmaceuticals, LPA physics, nuclear science, and high-intensity lasers, EUROPA offers a disruptive, scalable ARI production technology, compact, easy to operate and dismantle, unlocking new applications and markets.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Institut Mines-Telecom | Palaiseau | France | Coordinator |
| Laserlab-Europe Aisbl | Bruxelles / Brussel | Belgium | Participant |
| Forschungsverbund Berlin eV | Berlin | Germany | Third party |
| Focused Energy GmbH | Darmstadt | Germany | Participant |
| Gsi Helmholtzzentrum Fur Schwerionenforschung GmbH | Darmstadt | Germany | Participant |
| Consorcio Para El Diseno, Construccion, Equipamiento Y Explotacion Del Centro De Laseres Pulsados Ultracortos Ultraintensos | Villamayor | Spain | Participant |
| Adera SAS | Pessac | France | Third party |
| Amplitude | Pessac | France | Participant |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Commissariat a L Energie Atomique Et Aux Energies Alternatives | Paris | France | Participant |
| Commissariat a L Energie Atomique Et Aux Energies Alternatives | Paris | France | Third party |
| Thales Las France SAS | Elancourt | France | Participant |
| Universite De Bordeaux | Bordeaux | France | Participant |
| Institutul National De Cercetare-Dezvoltare Pentru Fizica Si Inginerie Nucleara-Horia Hulubei | Magurele | Romania | Participant |
| University of Strathclyde | Glasgow | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI